XLO
Xilio Therapeutics, Inc.0.6500
+0.0000+0%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
34.13MP/E (TTM)
-Basic EPS (TTM)
-0.61Dividend Yield
0%Recent Filings
10-K
FY2025 results
Xilio Therapeutics reported FY2025 net loss of $35.0M, improved from $58.2M in FY2024, driven by $43.8M collaboration revenue from AbbVie ($52.0M upfront) and Gilead milestone, versus $6.3M prior year. R&D expenses rose 36% to $56.0M on efarindodekin alfa Phase 2 initiation and XTX501 IND-enabling work, while vilastobart costs dipped on lower milestones; G&A up 20% to $29.7M. Cash reached $137.5M, bolstered by $47.0M follow-on proceeds and warrant exercises. Q4 momentum sustained preclinical advances; efarindodekin alfa Phase 1 data showed tolerability at 100x wild-type IL-12 MTD. Cash funds ops through 2027. Nasdaq delisting risk looms from low bid price.
8-K
Q4 profit, cash runway extended
8-K
1-for-14 reverse split filed
Xilio Therapeutics filed for a 1-for-14 reverse stock split, effective 5:00 p.m. ET on March 13, 2026, slashing outstanding shares from ~73.5 million to ~5.2 million. The move aims to meet Nasdaq's minimum bid price for continued listing. Trading resumes split-adjusted under 'XLO' on March 16. Cash replaces fractional shares.
8-K
Xilio updates pipeline, cash position
Xilio Therapeutics posted its March 9, 2026 corporate investor presentation under Item 7.01, spotlighting its masked immuno-oncology pipeline and $137.5M estimated cash as of December 31, 2025—funding operations through 2027. Key milestones include XTX501 IND submission mid-2026 for NSCLC and PSMA+STEAP1 development candidate nomination Q2 2026. Cash extends via potential $36.2M warrant exercises and partner fees.
8-K
Reverse split approved
Xilio Therapeutics stockholders overwhelmingly approved a reverse stock split on February 23, 2026, at a special meeting, with 55.4 million votes for versus 1.5 million against. The board holds discretion over the exact 1-for-2 to 1-for-30 ratio, timing, and implementation. No broker non-votes. Split aims to meet Nasdaq requirements.
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CMPX
Compass Therapeutics, Inc.
5.24+0.16
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MRKR
Marker Therapeutics, Inc.
1.27-0.12
QTTB
Q32 Bio Inc.
2.88-0.17
TIL
Instil Bio, Inc.
11.25+0.13
XBIT
XBiotech Inc.
2.45-0.08
XFOR
X4 Pharmaceuticals, Inc.
3.71-0.05
XRTX
XORTX Therapeutics Inc.
0.59-0.01